---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-047755"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:21:21.079992+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion Q4 net loss $29.3M; cash drops to $58.6M; interim CEO appointed, pivots to diabetes

## Summary
- Net loss $29.3M for Q4 2024 ($34.9M in Q4 2023); FY net loss $138.4M vs $117.3M.
- Cash reserves $58.6M at Dec 31, 2024, down from $177.2M a year earlier.
- Mick Hitchcock appointed interim CEO; all oncology trials terminated, focus shifts to diabetes/obesity.
- Icovamenib in severe insulin-deficient T2D: 1.47% HbA1c reduction at Week 26; FDA meeting planned H1 2025.
- BMF-650 (oral GLP-1 RA) IND submission planned H2 2025; preclinical appetite suppression data reported.

## SEC filing metadata
- accession: 0000950170-25-047755
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000095017025047755/0000950170-25-047755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000095017025047755/bmea-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-047755
- JSON: https://secwatch.observer/filing/0000950170-25-047755.json
- Plain text: https://secwatch.observer/filing/0000950170-25-047755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.